MEDIUM confidence: 100% data completeness, but the composite (57) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Buy-rated share 73% → 77% over ~3 months (+3pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $0.74 | $0.78 | +5.0% |
| Apr 2026 | $0.73 | $0.78 | +7.0% |
| Feb 2026 | $0.62 | $0.58 | -6.1% |
| Oct 2025 | $0.60 | $0.67 | +12.4% |
| Jul 2025 | $0.62 | $0.67 | +7.4% |
| Apr 2025 | $0.60 | $0.64 | +7.4% |
| Feb 2025 | $0.55 | $0.59 | +7.1% |
| Oct 2024 | $0.67 | $0.67 | +0.8% |
Net insider -$11.3M over 180 days (0 open-market buys, 23 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $5.2B— | $5.4B+2.9% | $5.0B-6.9% | $5.4B+8.6% | $6.1B+11.5% |
| EPS (dil.) | $2.38— | $2.44+2.5% | $2.30-5.7% | $6.97+203.0% | $1.83-73.7% |
| Free Cash Flow | $1.4B— | $953M-32.0% | $630M-34.0% | $290M-53.9% | $1.3B+360.5% |
| Gross Margin | 76.6% | 78.3%+1.7pp | 79.3%+1.0pp | 79.5%+0.2pp | 78.1%-1.3pp |
| Operating Margin | 30.8% | 31.6%+0.9pp | 28.5%-3.1pp | 25.3%-3.1pp | 27.0%+1.6pp |
| Net Margin | 28.7% | 28.3%-0.5pp | 28.0%-0.3pp | 76.7%+48.8pp | 17.7%-59.1pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 9.7%/yr (revenue basis).
Base free cash flow $751M (avg FY2023–FY2025; latest year $1.3B) · equity value $53.4B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 57 for Edwards Lifesciences Corporation suggests a neutral outlook, with the stock scoring high on risk and exhibiting strong momentum, but trading at a premium with a P/E of 53.3. The growth category is boosted by strong revenue and free cash flow growth, but hindered by a decline in EPS growth. The long-term and short-term scores are relatively aligned, with the short-term score slightly higher at 58, indicating a consistent view across different time horizons. Overall, the stock's high valuation and mixed growth metrics are balanced by its stable risk profile and positive momentum.